Stocks edge lower at the open as investors seek positive catalysts

U.S. stocks opened lower on Monday as investors found few reasons to keep pushing shares higher with major indexes near records and geopolitical uncertainty weighing on sentiment. Equities rallied Friday on the back of stronger-than-expected jobs data and news that President Donald Trump would roll back financial regulations, which lifted bank stocks. However, the impact of those factors may already be priced into shares, making further momentum hard to come by. The financial sector dropped 0.6%. The Dow Jones Industrial Average fell 61 points, or 0.3%, to 20,010, with Travelers Companies Inc. among the biggest movers in early trading. The insurance company fell 0.7% and was the biggest Dow decliner. The S&P 500 fell 4 points to 2,293, a decline of 0.2%. The Nasdaq Composite Index slid 12 points to 5,655 for a drop of 0.2%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Hasbro’s stock rockets toward record high after results, dividend hike

Shares of Hasbro Inc. rocketed 13% toward a record high in premarket trade Monday, after the toy seller’s fourth-quarter results beat expectations and the dividend was raised. The stock was on track to open above $93, above the record close of $87.94 on Nov. 25, 2016 and the all-time intraday high of $88.53 on April 19, 2016. Hasbro raised its quarterly dividend 12% to 57 cents a share from 51 cents a share, payable May 15 to shareholders of record on May 1. Based on Friday’s stock closing price of $82.63, the new annual dividend rate implies a dividend yield 2.76%, compared with the aggregate S&P 500 dividend yield of 2.06%, according to FactSet. Hasbro’s stock has tacked on 1.9% over the past three months through Friday, while the S&P 500 has gained 10%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Aratana Therapeutics’ stock tumbles after delay to commercialize pet drug

Shares of Aratana Therapeutics Inc. tumbled 9.1% in premarket trade Monday, after the pet therapeutics company disclosed that the Center for Veterinary Medicine requested more information about its appetite stimulation drug. Aratana said the request is related to the company’s post-approval supplement request to transfer the manufacturing of Tentyce to a new vendor. The company said it now expects Entyce to be commercially available by late 2017. The stock has more than doubled over the past 12 months through Friday, while the S&P 500 has gained 22%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Sysco tops profit estimates, shares pop 1.3% permarket

Food service company Sysco Corp. said Monday it had net income of $275 million, or 50 cents a share, in its fiscal second quarter, up from $272 million, or 48 cents a share, in the year- earlier period. Adjusted per-share earnings came to 58 cents. topping the 54 cents FactSet consensus. Sales climbed to $13.5 bllion from $12.2 billion, matching the FactSet consensus of $13.5 billion. U.S. sales came to $9.1 billion, down 0.5%, while international operations fame to $2.6 billion, up from $1.3 billion a year ago. Shares rose 1.3% in premarket trade, and are up 22% in the last 12 months, while the S&P 500 has gained 22.6%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Tiffany’s stock slumps after CEO steps down

Shares of Tiffany & Co. slumped 3.2% in premarket trade, after the high-end jewelry retailer said over the weekend that Chief Executive Frederic Cumenal stepped down, effective immediately, after 22 months in the role. Cumenal had joined Tiffany in March 2011 from LVMH Group, and was named CEO as of April 1, 2015. Tiffany’s stock has declined 6.6% through Friday with Cumenal as CEO, while online jewelry seller Blue Nile Inc. shares have soared 40.1% over the same time, Signet Jewelers Ltd. shares have plunged 44.7%, the SPDR S&P Retail ETF has tumbled 14.4% and the S&P 500 has climbed 11.5%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Icahn Enterprises prices rights offering at $53.71 per newly issued depositary unit

Icahn Enteprises LP , the investing arm of billionaire Carl Icahn, on Monday set the pricing for its previously announced rights offering. The company said each whole right will be priced at $53.71 and entitle the holder to one newly issued depositary unit of Icahn Enterprises. The company is intended to distribute the rights to record date unitholders on Feb. 9. Icahn Enteprrises stock was not yet active premarket, but has gained 16.9% in the last 12 months, while the S&P 500 has gained 22%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Tyson Foods stock soars 7% following strong earnings report

Shares of Tyson Foods soared 7% in premarket trade Monday after the company reported stronger-than-expected first-quarter earnings and sales and raised its annual outlook, citing strong beef and pork sales. The company reported net income of $593 million, or $1.59 a share, compared with $461 million, or $1.15, in the year-earlier period. Revenue for the three-month period increased to $9.18 billion compared with $9.15 billion in the year-earlier period. Analysts surveyed by FactSet had been calling for earnings of $1.27 on sales of $9.03 billion. The meat producer raised its full-year outlook to a range of $4.90 to $5.05 a share, compared with the consensus estimate of $4.89. As of Friday’s close, the company’s shares had been down 2.5% in the past three months, compared with a 10% increase for the S&P 500 .

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Airbnb to offer housing for 100,000 in need, pledges $4 million to help displaced people

Following a Super Bowl ad on accepting diversity Sunday night, home-sharing company Airbnb pledged to provide short-term housing for 100,000 people in need over five years. Initially, Airbnb said it would focus on refugees, disaster survivors and relief workers. Additionally, Airbnb pledged $4 million over four years to the International Rescue Committee. Airbnb was one of several companies that spoke out against President Donald Trump’s immigration ban and the company said it would offer free housing to refugees who were not allowed into the country following the ban.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Galena Biopharma stock surges 21% after independent group says breast cancer drug has no safety concerns

Galena Biopharma Inc. shares surged 20.8% in pre-market trade Monday after the company said an independent group of experts decided its breast cancer combination treatment in two mid-stage trials had no safety concerns and found neither to be futile. Galena is testing its NeuVax with chemotherapy drug trastuzumab in two clinical trials, one phase 2b and the other phase 2, to prevent recurrence of breast cancer. The Data Safety Monitoring Board’s findings mean the trials can proceed, Galena’s Executive Vice President Bijan Nejadnik said. The company ended a late-stage clinical trial of the same drug, Neuvax, last year on a different independent committee’s recommendation and the committee’s futility concerns. An interim efficacy analysis for the phase 2b trial of NeuVax and trastuzumab is expected near the end of this year, Galena said. Galena shares were priced at $1.20 as of Friday’s close. Galena shares have dropped 68.4% over the last three months, compared with a 10.2% rise in the S&P 500 .

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Hasbro’s stock surges after profit and sales rise above expectations

Shares of Hasbro Inc. surged 4.1% in premarket trade Monday, after the toy maker reported profit and sales that rose above expectations. Earnings for the quarter to Dec. 25 rose to $192.7 million, or $1.52 a share, from $175.8 million, or $1.39 a share, in the same period a year ago. Excluding non-recurring items, adjusted earnings per share came to $1.64, beating the FactSet consensus of $1.27. Revenue grew to $1.63 billion from $1.47 billion, above the FactSet consensus of $1.50 billion. Boys category revenue fell 3% to $552.3 million, but was above the FactSet consensus of $534.9 million, while girls category revenue jumped 52% to $394.2 million, beating the FactSet consensus of $343.8 million. The stock has run up 12% over the past 12 months through Friday, while the S&P 500 has climbed 22%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News